S100A6 and Its Brain Ligands in Neurodegenerative Disorders
The S100A6 protein is present in different mammalian cells and tissues including the brain. It binds Ca<sup>2+</sup> and Zn<sup>2+</sup> and interacts with many target proteins/ligands. The best characterized ligands of S100A6, expressed at high level in the brain, include Ca...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-06-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/21/11/3979 |
| _version_ | 1797566395413692416 |
|---|---|
| author | Anna Filipek Wiesława Leśniak |
| author_facet | Anna Filipek Wiesława Leśniak |
| author_sort | Anna Filipek |
| collection | DOAJ |
| description | The S100A6 protein is present in different mammalian cells and tissues including the brain. It binds Ca<sup>2+</sup> and Zn<sup>2+</sup> and interacts with many target proteins/ligands. The best characterized ligands of S100A6, expressed at high level in the brain, include CacyBP/SIP and Sgt1. Research concerning the functional role of S100A6 and these two ligands indicates that they are involved in various signaling pathways that regulate cell proliferation, differentiation, cytoskeletal organization, and others. In this review, we focused on the expression/localization of these proteins in the brain and on their possible role in neurodegenerative diseases. Published results demonstrate that S100A6, CacyBP/SIP, and Sgt1 are expressed in various brain structures and in the spinal cord and can be found in different cell types including neurons and astrocytes. When it comes to their possible involvement in nervous system pathology, it is evident that their expression/level and/or subcellular localization is changed when compared to normal conditions. Among diseases in which such changes have been observed are Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), epileptogenesis, Parkinson’s disease (PD), Huntington’s disease (HD), and others. |
| first_indexed | 2024-03-10T19:27:08Z |
| format | Article |
| id | doaj.art-cee1046d9e3c4511a356d88d8af617c8 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T19:27:08Z |
| publishDate | 2020-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-cee1046d9e3c4511a356d88d8af617c82023-11-20T02:30:39ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-06-012111397910.3390/ijms21113979S100A6 and Its Brain Ligands in Neurodegenerative DisordersAnna Filipek0Wiesława Leśniak1Nencki Institute of Experimental Biology, Polish Academy of Sciences, 3 Pasteur Street, 02-093 Warsaw, PolandNencki Institute of Experimental Biology, Polish Academy of Sciences, 3 Pasteur Street, 02-093 Warsaw, PolandThe S100A6 protein is present in different mammalian cells and tissues including the brain. It binds Ca<sup>2+</sup> and Zn<sup>2+</sup> and interacts with many target proteins/ligands. The best characterized ligands of S100A6, expressed at high level in the brain, include CacyBP/SIP and Sgt1. Research concerning the functional role of S100A6 and these two ligands indicates that they are involved in various signaling pathways that regulate cell proliferation, differentiation, cytoskeletal organization, and others. In this review, we focused on the expression/localization of these proteins in the brain and on their possible role in neurodegenerative diseases. Published results demonstrate that S100A6, CacyBP/SIP, and Sgt1 are expressed in various brain structures and in the spinal cord and can be found in different cell types including neurons and astrocytes. When it comes to their possible involvement in nervous system pathology, it is evident that their expression/level and/or subcellular localization is changed when compared to normal conditions. Among diseases in which such changes have been observed are Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), epileptogenesis, Parkinson’s disease (PD), Huntington’s disease (HD), and others.https://www.mdpi.com/1422-0067/21/11/3979S100A6CacyBP/SIPSgt1neurodegenerationβ amyloid plaquesneurofibrillary tangles |
| spellingShingle | Anna Filipek Wiesława Leśniak S100A6 and Its Brain Ligands in Neurodegenerative Disorders International Journal of Molecular Sciences S100A6 CacyBP/SIP Sgt1 neurodegeneration β amyloid plaques neurofibrillary tangles |
| title | S100A6 and Its Brain Ligands in Neurodegenerative Disorders |
| title_full | S100A6 and Its Brain Ligands in Neurodegenerative Disorders |
| title_fullStr | S100A6 and Its Brain Ligands in Neurodegenerative Disorders |
| title_full_unstemmed | S100A6 and Its Brain Ligands in Neurodegenerative Disorders |
| title_short | S100A6 and Its Brain Ligands in Neurodegenerative Disorders |
| title_sort | s100a6 and its brain ligands in neurodegenerative disorders |
| topic | S100A6 CacyBP/SIP Sgt1 neurodegeneration β amyloid plaques neurofibrillary tangles |
| url | https://www.mdpi.com/1422-0067/21/11/3979 |
| work_keys_str_mv | AT annafilipek s100a6anditsbrainligandsinneurodegenerativedisorders AT wiesławalesniak s100a6anditsbrainligandsinneurodegenerativedisorders |